Alan S. Go, MD
Year elected: 2008
Current membership category: Active
Regional Medical Director, Clinical Trials Program; Associate Director, Cardiovascular and Metabolic Conditions Research; Professor of Epidemiology, Biostatistics and Medicine, UCSF; Professor of Medicine, Health Research and Policy, Stanford Univers
Kaiser Permanente Northern California
Division of Research
2000 Broadway
Oakland, CA 94612-2304
United States of America
Phone: 510-891-3422
Facsimile: 510-891-3508
Email: alan.s.go@kp.org
Website: https://divisionofresearch.kaiserpermanente.org/researchers/go-alan

Biographical statement

Dr. Go is Director of the Comprehensive Clinical Research Unit, Chief of the Cardiovascular and Metabolic Conditions Section at the Division of Research, and Regional Medical Director of Clinical Trials at Kaiser Permanente Northern California. He is also Associate Professor of Epidemiology, Biostatistics and Medicine at the University of California, San Francisco and Consulting Professor in the Department of Health Research and Policy at Stanford University. He is an internationally-recognized cardiovascular and renal epidemiologist, health services and outcomes researcher,and clinical trialist. Dr. Go has made seminal scientific and methodological contributions in cardiovascular and cardio-renal epidemiology as well as evaluation of the translation of randomized trials into clinical practice. He has achieved this through a coordinated research program ranging from manipulating large electronic databases to prospective cohorts to initiating development of a regional clinical trial consortium and a national cardiovascular research network. For example, among 1.1 million adults, he provided compelling evidence that even mild chronic kidney disease—affecting many individuals with serum creatinine concentrations previously considered to be “normal”—significantly increases the risks for cardiovascular disease, hospitalization, and death. Dr. Go also delineated the population prevalence of atrial fibrillation, a potent stroke risk factor, and provided the first large-scale evidence that oral vitamin K antagonists prevent ischemic stroke in persons with atrial fibrillation in the general population nearly as effectively as seen in randomized trials of highly selected samples. Overall, the theme of Dr. Go’s work is to improve cardiovascular risk prediction, prevention and optimal treatment, and he has taken a multi-faceted approach through clinical investigations at the levels of genetics, circulating biomarkers, clinical characteristics, and practice patterns for atherosclerotic vascular disease, heart failure, kidney disease, atrial fibrillation and stroke.

Institutional affiliations

Kaiser Permanente of Northern California (Primary)
University of California, San Francisco, School of Medicine (Secondary)
Stanford University School of Medicine (Tertiary)

Specialties

Internal Medicine